Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
Eur J Cancer. 2021 May;148:382-394. doi: 10.1016/j.ejca.2021.02.028. Epub 2021 Mar 29.
Eur J Cancer. 2021.
PMID: 33794440
Clinical Trial.
Atezolizumab in the treatment of metastatic triple-negative breast cancer.
Pérez-García J, Soberino J, Racca F, Gion M, Stradella A, Cortés J.
Pérez-García J, et al. Among authors: soberino j.
Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25.
Expert Opin Biol Ther. 2020.
PMID: 32450725
Review.
Item in Clipboard
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
Chic N, Schettini F, Brasó-Maristany F, Sanfeliu E, Adamo B, Vidal M, Martínez D, Galván P, González-Farré B, Cortés J, Gavilá J, Saura C, Oliveira M, Pernas S, Martínez-Sáez O, Soberino J, Ciruelos E, Carey LA, Muñoz M, Perou CM, Pascual T, Bellet M, Prat A.
Chic N, et al. Among authors: soberino j.
EBioMedicine. 2021 Jul;69:103451. doi: 10.1016/j.ebiom.2021.103451. Epub 2021 Jun 20.
EBioMedicine. 2021.
PMID: 34161883
Free PMC article.
Clinical Trial.
Item in Clipboard
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators.
Schmid P, et al.
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
N Engl J Med. 2022.
PMID: 35139274
Clinical Trial.
Item in Clipboard
Targeting FGFR pathway in breast cancer.
Perez-Garcia J, Muñoz-Couselo E, Soberino J, Racca F, Cortes J.
Perez-Garcia J, et al. Among authors: soberino j.
Breast. 2018 Feb;37:126-133. doi: 10.1016/j.breast.2017.10.014. Epub 2017 Nov 20.
Breast. 2018.
PMID: 29156384
Review.
Item in Clipboard
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators.
Miles D, et al.
Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2.
Ann Oncol. 2021.
PMID: 34224826
Free article.
Clinical Trial.
Item in Clipboard
Clinical Implications of Extracellular HMGA1 in Breast Cancer.
Méndez O, Pérez J, Soberino J, Racca F, Cortés J, Villanueva J.
Méndez O, et al. Among authors: soberino j.
Int J Mol Sci. 2019 Nov 26;20(23):5950. doi: 10.3390/ijms20235950.
Int J Mol Sci. 2019.
PMID: 31779212
Free PMC article.
Review.
Item in Clipboard
Cite
Cite